

IFW

Atty. Docket No.: 8654/2222

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wilson & Siim
Serial No.: 10/790,943
Filed: March 2, 2004
Entitled: Anti-Cancer Combinations

Examiner: Delacroix M. C.
Group Art Unit: 1614
Conf. No.: 2176

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:


1. Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of Cited References; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 8654/2222. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: 8/3/05

Name: Matthew Beaudet
Registration No.: 50,649
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wilson, et al.
Serial No.: 10/790,943
Filed: March 2, 2004
Entitled: Anti-Cancer Combinations

Examiner: Delacroix M. C.
Group Art Unit: 1614
Conf. No.: 2176

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Supplemental Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Pursuant to CFR § 1.97(c)(2), because this Statement is being submitted after the mailing of the first Office Action on the merits, please charge Deposit Account 16-0085, Reference 8654/2222 for the requisite fees.

Date:

8/3/05

Respectfully submitted,

Name: Matthew Beaudet

Registration No.: 50,649

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 8654/2222		Serial No. 10/790,943	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Applicant(s): Wilson & Siim			
				Filing Date: March 2, 2004		Group: 1614	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	1	Showalter & Hollis; "Potential Antitumor Agents. 61. Structure-Activity Relationships for In Vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids"; 1991; <u>Chemtracts: Org. Chem.</u> 4(2): 168-171.					
	2	Shoemaker, et al.; "Pleiotropic Resistance and Drug Development"; 1986; <u>Progress Clin. Biol. Res.</u> ; 223: 143-149.					
	3	Van der Auwera, et al.; "Conformational Features of Four Model Tripeptides having Piv-Pro-MeXaa-Nme ₂ Sequences"; 1988; <u>Bull. Soc. Chim. Belg.</u> ; 97(3): 199-207.					
	4	Ching & Baguley; "The Anti-Tumour and Immune-Modulatory Activites of Flavone Acetic and Xanthone Acetic Acids"; 1990; <u>N.P. Das (ed.), flavanoids in Biology and Medicine III. Proceedings of the 3rd International Symposium on Flavonoids in Biology and Medicine, Singapore; National University of Singapore</u> ; 381-391.					
	5	Rustin, et al.; "Impact on Tumour Perfusion Measured by Dynamic Magnetic Resonance Imaging (MRI), in the Phase 1 Trial of 5,6-dimethylxanthenone-4-acetic Acid (DMXAA)"; <u>Proc. 10th NCI-EORTC Symp. New Drugs</u> ; 1998; 10: 126.					
	6	Bibby, et al.; "Reduction of Tumor Blood Flow by Flavone Acetic Acid: A Possible Component of Therapy"; 1989; <u>J. Natl. Cancer Inst.</u> ; 81: 216-220.					
	7	Zhou, et al.; "Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes"; 2001; <u>Br. J. Clin. Pharmacol.</u> ; 52: 129-136.					
	8.	Rewcastle, et al.; "Potential Antitumor Agents. 61. Structure-Activity Relationships for In Vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids"; 1991; <u>J. Med. Chem.</u> ; 34: 217-222.					
EXAMINER				DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> <p>**Copies of references not provided at the time of this submission.</p>							